Bio Developments

FDA Faces Uncertainty with Sequester, Continuing Resolution

FDA Faces Uncertainty with Sequester, Continuing Resolution

By Zachary Brennan

The US FDA’s ability to inspect facilities, trial sites, and deal with all but its most pressing priorities will be restricted by mandatory government spending cuts according to the Alliance for a Stronger FDA.

DSM to Supply Cancer Drug for Eisai

DSM to Supply Cancer Drug for Eisai

By Dan Stanton

Eisai says its US supply agreement with DSM offers an alternate manufacturing facility and ensures a strengthened supply line.

Chinese CRO Partnerships Focus on Bioavailability, PK/PD Analysis

Chinese CRO Partnerships Focus on Bioavailability, PK/PD Analysis

By Zachary Brennan

Contract drug developer Particle Sciences has recently chosen China-based CRO Crystal Pharmatech to analyse the bioavailability and material properties of its developing compounds, and the collaboration may turn into a joint venture.

People on the Move: Jobs in Pharma

People on the Move: Jobs in Pharma

By Dan Stanton

In-Pharmatechnologist.com presents its latest round-up of the movers and shakers in the world of pharmaceuticals.

PPD Expands Central Lab Services in Brussels, Singapore

PPD Expands Central Lab Services in Brussels, Singapore

By Zachary Brennan

PPD has expanded its central lab testing services at its Brussels and Singapore labs and will offer additional services in microbiology, peripheral blood mononuclear cell and molecular pathology services.

Johnson Matthey aims to optimize API biz

Johnson Matthey to optimise API biz; Fine Chem forecasts roundup

By Gareth Macdonald

in-Pharmatechnologist.com presents a roundup of news in the fine chemicals sector, beginning with Johnson Matthey which has started a review of its active pharmaceutical ingredient (API) business after competition in the UK impacted its third quarter...

Follow us

Webinars